{
    "clinical_study": {
        "@rank": "106104", 
        "brief_summary": {
            "textblock": "To assess the safety and efficacy of subcutaneous sargramostim ( granulocyte-macrophage\n      colony-stimulating factor; GM-CSF ) in increasing and maintaining the granulocyte count in\n      HIV-infected children who have developed granulocytopenia as a result of continuous\n      intravenous ( CIV ) zidovudine ( AZT ). To assess the short-term and long-term effects of\n      concomitant GM-CSF on other hematologic parameters. To assess the potential therapeutic\n      benefit of concomitant GM-CSF and AZT on the natural history of HIV infection and associated\n      infectious complications."
        }, 
        "brief_title": "A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine", 
        "condition": [
            "HIV Infections", 
            "Cytopenias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Neutropenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT) on NIAID 86-C-175.\n\n        Patients must have:\n\n          -  Diagnosis of perinatal or transfusion acquired AIDS or AIDS related complex.\n\n          -  Granulocytopenia (< or = to 800 cells/mm3) associated with the administration of AZT\n             on protocol NIAID 86-C-175.\n\n          -  Life expectancy > 3 months.\n\n          -  Functioning indwelling central venous access device in place.\n\n        Prior Medication:\n\n        Allowed within 48 hours of study entry:\n\n          -  Prophylactic antibiotics.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Critically ill or clinically unstable.\n\n          -  Significant, active opportunistic or other infection requiring specific drug therapy\n             at time of study entry.\n\n          -  Ongoing IV alimentation.\n\n          -  Uncorrected nutritional deficiencies that may contribute to anemia and/or leukopenia.\n\n          -  Past history of or current evidence for any chronic hematologic disorder other than\n             hemophilia A or B, anemia of chronic disease or anemia related to HIV infection.\n\n          -  Malignancy likely to require systemic treatment during study.\n\n        Patients with the following are excluded:\n\n          -  Critically ill, clinically unstable, or with concomitant diseases listed in Patient\n             Exclusion Co-existing Conditions.\n\n          -  Hypersensitivity to zidovudine (AZT) or any other nucleoside analog.\n\n        Prior Medication:\n\n        Excluded within 48 hours of study entry:\n\n          -  Antibiotics.\n\n          -  Excluded within 30 days of study entry:\n\n          -  Antiretroviral agents other than zidovudine (AZT).\n\n          -  Acyclovir.\n\n          -  Ganciclovir.\n\n          -  Any investigational drug.\n\n          -  Immunomodulating drugs.\n\n          -  Cytolytic chemotherapeutic agents.\n\n          -  Corticosteroids.\n\n          -  Immunoglobulin preparations.\n\n          -  Excluded within 4 months of study entry:\n\n          -  Suramin.\n\n        Prior Treatment:\n\n        Excluded within 6 months of study entry:\n\n          -  Bone marrow transplantation.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  Lymphocyte transfusions.\n\n          -  Radiation therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Months"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002263", 
            "org_study_id": "067B", 
            "secondary_id": "206"
        }, 
        "intervention": [
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Sargramostim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Molgramostim"
            ]
        }, 
        "keyword": [
            "Pilot Projects", 
            "Neutropenia", 
            "Granulocyte-Macrophage Colony-Stimulating Factor", 
            "Acquired Immunodeficiency Syndrome", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "Natl Cancer Institute / HIV / AIDS Malignancy Branch"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002263"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1990"
    }, 
    "geocoordinates": {
        "Natl Cancer Institute / HIV / AIDS Malignancy Branch": "38.985 -77.095"
    }
}